Today's New England Journal of Medicine disclosed the effectiveness of a left ventricular assist device (LVAD) and medical regimen at reverse-remodeling chronically dilated hearts back to near-normal in a small subset of 15 patients. While these data were novel and encouraging - one wonders if these individuals could have been spared the need for left-ventricular assist devices if they had had implementation of biventricular pacing earlier in their clinical course.
I was unable to find mention of the EKG duration of the patients followed in the New England Journal of Medicine article, nor did it appear that ANY of these patients had received a biventricular pacing device. I suppose I should not be surprised, since the New England Journal of Medicine study was funded by the LVAD manufacturer, Thoratec. But excluding this data omits important data regarding these severe heart failure patients: was all done for these patients before LVAD implantation? Although I appreciate that not all heart failure can be detected early, 12 of 15 of the patients in this study had been treated for at least 6 months before LVAD implantation without biventricular pacing, leading me to wonder if the implantation of a biventricular device could have prevented the need for the LVAD.
Biventricular pacing has now been firmly established as an effective means of treating patients with severe congestive heart failure on maximal medical therapy. It should probably be considered the standard of care, in my view, for patients with severe cardiomyopathy refractory to medical therapy with evidence of conduction delay during activation of the left ventricle (QRS duration >=120 msec). Biventricular pacing involves placing a left ventricular pacing lead in addition to a right ventricular pacing lead to re-coordinate the pumping action of the ventricular pumping chambers. Clinical studies have demonstrated that approximately 2/3rds of symptomatic patients have an improvement in their 6-minute hall walk test (walking on average an additional 50 meters), improve by about one New Heart Association heart failure class, and have improved quality of life using self-assessment measures. More importantly, the COMPANION and recently-released CARE-HF trials have demonstrated a mortality benefit to patients receiving biventricular pacing devices. Anecdotally, I have seen complete normalization of left ventricular function in a small subset of patients with non-ischemic cardiomyopathy (like those the the NEJM article) after this therapy has been deployed.
It should be noted that the effect of biventricular pacing trials has been so impressive that earlier intervention of biventricular pacing in heart failure is now being evaluated in the BLOCK-HF trial and its application to patients with normal EKG duration in St. Jude Medical's RethinQ trial.
Hopefully we'll remember the benefit of biventricular pacing therapy (with or without an implantable defibrillator) in our sickest heart failure patients and apply this before the need for an LVAD arises.
-Wes
Photo credit.
are you seeing good results with crt in your patients with severe heart failure and rbbb?
ReplyDeleteAnony-
ReplyDeleteMy experience with biV pacing in RBBB has been limited - I have implanted far more LBBB than RBBB patients. Few data exist in large numbers regarding biV pacing and RBBB. In the MIRACLE and CONTAK-CD trials, there was no difference in response rates between LBBB and RBBB patients, but too few RBBB existed to permit meaningful subgroup analysis (only ~10% of patients in the MIRACLE trial had RBBB).
There has been novel work in pediatric patients with RV overload states and RBBB in a very small subset of patients (7) using RV pacing to "resynchronize" the RBBB pattern that has demonstrated good hemodynamic response (Circulation 2003;107:2287) but large series evaluating RBBB and biV pacing have not been forthcoming to date. One study (Garrigue S, et al. Usefulness of biventricular pacing in patients with congestive heart failure and right bundle branch block. Am J Cardiol. 2001; 88: 1436–1441.) has suggested biV pacing might be helpful, but only in patients with echo-documented intraventricular dyssynchrony.
Hi, I have LBBB and IDCM. My EF has been going down 04.02=65%, 08.04=twin birth, 02.05=30%, 07.06=20%, 01.07=15-20%.
ReplyDeleteWhile my EF is low. I can go on the treadmill for 60 minutes, daily. I have no congestion. I have no edema. I'm taking 18.75 Coreg BID. Am I one of these early heart failure patients that you are speaking about?
Thrice-
ReplyDeleteYou don't really "fit" in any of the trials performed to date. There are, however, reasonable data that folks with ejection fractions as low as yours might live longer if a defibrillator were implanted. Certainly good data exist on the benefits of carvedilol (Coreg) in heart failure. Certainly LVAD therapy in your case is too extreme, but consideration of prophylactic implantation of a biventricular defibrillator as "primary prevention" of sudden death should be discussed with your doctor.